Empagliflozin: SGLT2 inhibitor
Phase 3
Indication: Prevention of heart failure (HF) post myocardial infarction (MI)
Anchored in external partnership or acquisition
US FDA Fast Track Designation
Empagliflozin (marketed as Jardiance®) is an oral, once-daily, highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor Empagliflozin is the first clinically proven therapy to improve outcomes across the full spectrum of heart failure patients.
The EMPACT-MI collaboration with Duke Clinical Research Institute investigates whether empagliflozin can improve outcomes in adults who have had an acute heart attack and is expected to conclude in 2023.